Impact of a cardiac risk reduction program in vulnerable patients hospitalized with coronary artery disease

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 768-775

  Krantz, Mori J ^a   Havranek, Edward P ^a   Mehler, Philip S ^a   Haynes, Deborah K ^a   Long, Carlin S ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

American Heart Association; Clinical guidelines; Coronary artery disease; Get with the Guidelines Program; Quality improvement; Vulnerable patients

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; ETHNIC GROUP; FEMALE; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HEART PROTECTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NURSING; PATIENT COUNSELING; PATIENT EDUCATION; POVERTY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK REDUCTION; SOCIOECONOMICS; UNITED STATES;

COLORADO; CORONARY ARTERIOSCLEROSIS; CORONARY CARE UNITS; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, MUNICIPAL; HUMANS; INTERNSHIP AND RESIDENCY; INTERVENTION STUDIES; MALE; MIDDLE AGED; NURSE ADMINISTRATORS; PATIENT EDUCATION; PROGRAM EVALUATION; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; VULNERABLE POPULATIONS;

EID: 2942614743     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.768.36061     Document Type: Article

References (48)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2003.
2. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
4. Long-term Treatment with Pravastatin in Ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Scandinavian Simvastatin Survival Study (4S) Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
6. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
7. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31.
8. Norwegian Multicentre Group. Timolol induced reduction in mortality in patients surviving myocardial infarction. N Engl J Med 1981;304:801-7.
9. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with chronic stable angina) J Am Coll Cardiol 1999;33:2092-197.
10. Smith SC Jr, Blair SN, Criqui MH, et al. American Heart Association consensus panel statement: preventing heart attack and death in patients with coronary disease: the secondary prevention panel. J Am Coll Cardiol 1995;26:292-4.
11. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
12. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after acute myocardial infarction. N Engl J Med 1998;339:489-97.
13. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 to 1999: the national registry of myocardial infarction 1, 2, and 3. J Am Coll Cardiol 2000;36:2056-63.
14. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the national registry of myocardial infarction 3. Circulation 2001;103:38-44.
15. European Action on Secondary Prevention Through Intervention to Reduce Events (EUROASPIRE) I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
16. Rathore SS, Berger AK, Weinfurt KP, et al. Race, sex, poverty and the medical treatment of acute myocardial infarction in the elderly. Circulation 2000;102:642-8.
17. Cooper R, Cutler I, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137-47.
18. Gabow P, Eisert S, Wright R. Denver health: a model for the integration of a public hospital and community health centers. Ann Intern Med 2003;138:143-9.
19. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
20. Phillips L, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34.
21. Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002;162:797-804.
22. Caban MD, Rand CS, Powe NK, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;280:1458-65.
23. Birtcher KK, Bowden C, Ballantyne CM, et al. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol 2000;85:30A-5.
24. Lacy CR, Suh DC, Barone JA, et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 2002;162:468-73.
25. Fonarow GC, Gawlinski A. Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles. Am J Cardiol 2000;85:10A-17.
26. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001;87:819-22.
27. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003;326:84-7.
28. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.
29. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-6.
30. Stenestrand U, Wallentin L. Swedish register of cardiac intensive care (RIKS-HIA): early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
31. Gillum RF, Gillum BS, Francis CK. Coronary revascularization and cardiac catheterization in the United States: trends in racial differences. J Am Coll Cardiol 1997;29:1557-62.
32. Chen J, Rathore SS, Radford MJ, et al. Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med 2001;344:1443-9.
33. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians: progress and missed opportunities. JAMA 1993;269:1133-8.
34. Sempos C, Cooper R, Kovar MG, et al. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health 1988;78:1422-7.
35. Francis CK. Research in coronary heart disease in blacks: issues and challenges. J Health Care Poor Underserved 1997;8:250-69.
36. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the third national health and nutrition examination survey. Arch Intern Med 2002;162:929-35.
37. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in Medicare managed care, JAMA 2002;287:1288-94.
38. Hardarson T, Gardarsdottir M, Gudmundsson KT, et al. The relationship between educational level and mortality: the Reykjavik study. J Intern Med 2001;249:495-502.
39. Shi L. The convergence of vulnerable characteristics and health insurance in the U.S. Soc Sci Med 2001;53:519-29.
40. Andrulis DP. Access to care is the centerpiece in the elimination of socioeconomic disparities in health. Ann Intern Med 1998;129:412-16.
41. Anonymous. Progress report for Hispanic Americans. Washington, DC: U.S. Department of Health and Human Services, 1993.
42. Shea S, Misra D, Ehrlich MH, et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992;82:1607-12.
43. Lasater LM, Davidson AJ, Steiner JF, Mehler PS. Glycemic control in English- vs Spanish-speaking Hispanic patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:77-82.
44. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Int Med 2001;161:183-8.
45. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12.
46. Heart Protection Study Collaborative Group. Medical Research Council/British Heart Foundation (MRC/BHF) heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
47. Brugada R, Wenger NK, Jacobson TA, Clark WS, Cotsonis G, Iglesias A. Changes in plasma cholesterol levels after hospitalization for acute coronary events. Cardiology 1996;87:194-9.
48. LaBresh KA, Tyler PA. A collaborative model for hospital-based cardiovascular secondary prevention. Q Manage Health Care 2003;12:20-7.